BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34054800)

  • 1. Postpartum HPV Vaccination Rate and Differences in Background Characteristics Between HPV Vaccinated and Unvaccinated Postpartum Women: Strict Monitoring and Follow-Up of Postpartum HPV Vaccination Program.
    Lee CY; Tseng CJ; Chang CC; Lee MC; Yang SF
    Front Immunol; 2021; 12():626582. PubMed ID: 34054800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
    Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
    Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus vaccines.
    Satyaprakash A; Creed R; Ravanfar P; Mendoza N
    Dermatol Ther; 2009; 22(2):150-7. PubMed ID: 19335726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial.
    Gray P; Kann H; Pimenoff VN; Eriksson T; Luostarinen T; Vänskä S; Surcel HM; Faust H; Dillner J; Lehtinen M
    PLoS Med; 2021 Jun; 18(6):e1003588. PubMed ID: 34097688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Have preferences of girls changed almost 3 years after the much debated start of the HPV vaccination program in The Netherlands? A discrete choice experiment.
    Hofman R; de Bekker-Grob EW; Richardus JH; de Koning HJ; van Ballegooijen M; Korfage IJ
    PLoS One; 2014; 9(8):e104772. PubMed ID: 25136919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
    Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
    BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
    Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
    Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptance and compliance with postpartum human papillomavirus vaccination.
    Wright JD; Govindappagari S; Pawar N; Cleary K; Burke WM; Devine PC; Lu YS; Tsai WY; Lewin SN; Herzog TJ
    Obstet Gynecol; 2012 Oct; 120(4):771-82. PubMed ID: 22996094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative and qualitative assessment of an all-inclusive postpartum human papillomavirus vaccination program.
    Berenson AB; Hirth JM; Kuo YF; Rupp RE
    Am J Obstet Gynecol; 2021 May; 224(5):504.e1-504.e9. PubMed ID: 33248134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.
    Julius JM; Ramondeta L; Tipton KA; Lal LS; Schneider K; Smith JA
    Pharmacotherapy; 2011 Mar; 31(3):280-97. PubMed ID: 21361739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Papillomavirus Vaccination and Pap Smear Uptake Among Young Women in the United States: Role of Provider and Patient.
    Guo F; Hirth JM; Berenson AB
    J Womens Health (Larchmt); 2017 Oct; 26(10):1114-1122. PubMed ID: 28841084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
    Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
    Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A human papillomavirus vaccination program for low-income postpartum women.
    Berenson AB; Rahman M; Hirth JM; Rupp RE; Sarpong KO
    Am J Obstet Gynecol; 2016 Sep; 215(3):318.e1-9. PubMed ID: 26899907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
    Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
    Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake of three doses of HPV vaccine by primary school girls in Eldoret, Kenya; a prospective cohort study in a malaria endemic setting.
    Mabeya H; Menon S; Weyers S; Naanyu V; Mwaliko E; Kirop E; Orango O; Vermandere H; Vanden Broeck D
    BMC Cancer; 2018 May; 18(1):557. PubMed ID: 29751793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
    Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
    BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with HPV vaccination among adult women in Quebec.
    Kiely M; Sauvageau C; Dubé E; Deceuninck G; De Wals P
    Hum Vaccin Immunother; 2013 Jul; 9(7):1421-4. PubMed ID: 23571165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.